Part 2 of the study will assess WTX-124 in advanced or metastatic cutaneous malignant melanoma or advanced or metastatic renal cell carcinoma patients. Credit: Julio C. Valencia / commons.wikimedia.org.

Werewolf Therapeutics has dosed the first subject in the Phase I/Ib clinical trial of WTX-124 to treat solid tumours. 

The multicentre, first-in-human, open-label trial will analyse WTX-124 as a single agent, and along with Merck’s Keytruda (pembrolizumab), in immunosensitive advanced or metastatic solid tumour patients. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

These patients should have failed standard of care, including checkpoint inhibitor treatment.

Part 1 of the trial will be a dose escalation study analysing WTX-124 as monotherapy, along with pembrolizumab. 

Part 2 will have four arms where the therapy will be evaluated as a single agent, and with pembrolizumab in advanced or metastatic cutaneous malignant melanoma, or advanced or metastatic renal cell carcinoma patients.

See Also:

A lead INDUKINE molecule of the company, WTX-124 is a conditionally-activated Interleukin-2 (IL-2) prodrug.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The design of WTX-124 comprises a wild-type IL-2 cytokine attached to an inactivation domain for hindering activation in off-target tissue, a tumour protease-sensitive linker that permits the activation in the tumour microenvironment (TME). 

It also contains a half-life extension domain to boost tumour exposure. 

In preclinical models, IL-2’s selective release in the TME elicits anti-tumour immune responses causing tumour regressions and reducing toxicities linked to recombinant IL-2’s systemic delivery.

Werewolf Therapeutics founder and CEO Daniel Hicklin said: “WTX-124 is the first programme from our portfolio of novel INDUKINE molecules to enter the clinic, and its progress into clinical investigation further highlights our team’s ability to execute efficiently and move our pipeline forward. 

“We believe WTX-124 presents a tremendous opportunity, not only to improve outcomes for patients with hard-to-treat solid tumours but also to validate our novel approach of developing conditionally activated cytokines as innovative cancer therapy.”